×
Back to Agenda
Session 2: Is Zynteglo representative for the ATMPs failure in Europe? Are EU systems broken for innovative therapies?
Session Chair(s)
Alexander Natz, JD
Secretary General, European Confederation of Pharmaceutical Entrepreneurs, Belgium
Topics covered in this session include:
- Case study & domino effect
- The regulatory aspects
- Historical background for withdrawals
Speaker(s)
Sophie Schmitz
Managing Partner, P4A Partners for Access, Netherlands
Oswald Bentinck
Vice President, Global Head of Value & Access, Rocket Pharmaceuticals, Inc., United States
The Zolgensma Experience – Can one-time ATMP’s be successfully commercialized in Europe?
Have an account?